| MeSH term | MeSH ID | Detail |
|---|---|---|
| Asthenia | D001247 | 5 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Breast Neoplasms | D001943 | 24 associated lipids |
| Bronchial Spasm | D001986 | 18 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Hyperplasia | D006965 | 34 associated lipids |
| Hypopharyngeal Neoplasms | D007012 | 1 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Yue XF et al. | Cytotoxic activity of trewiasine in 4 human cancer cell lines and 5 murine tumors. | 1992 | Zhongguo Yao Li Xue Bao | pmid:1442109 |
| Fan YJ et al. | [Effect of maytansine on the cell cycle of Ehrlich ascites carcinoma cells in mice]. | 1985 | Zhongguo Yao Li Xue Bao | pmid:3158164 |
| Yang JL et al. | [Antitumor activity of trewiasine in vitro and in vivo]. | 1988 | Zhongguo Yao Li Xue Bao | pmid:3256213 |
| Wang XF et al. | [Studies on the antitumor constituents of Maytenus confertiflora Luo et Chen (Celastraceae). II. Isolation and characterization of maytansine and maytanprine from the stems]. | 1981 | Yao Xue Xue Bao | pmid:7324964 |
| Fan YJ et al. | [Use of 1,2:5,6-dianhydrogalactitol in combination with maytansine in experimental tumor therapy]. | 1983 | Yao Xue Xue Bao | pmid:6677049 |
| Vilela MD et al. | Progressively Enlarging Cerebellar Hematoma Concurrent with T-DM1 Treatment. | 2018 | World Neurosurg | pmid:29274446 |
| Niell HB et al. | Effect of concentration and time of drug exposure on clonal growth of murine bladder cancer. | 1985 | Urology | pmid:2579500 |
| Milowsky MI et al. | Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. | 2016 | Urol. Oncol. | pmid:27765518 |
| Roviello G et al. | Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. | 2016 | Tumour Biol. | pmid:26566626 |
| Faião-Flores F et al. | Bcl-2 family proteins and cytoskeleton changes involved in DM-1 cytotoxic effect on melanoma cells. | 2013 | Tumour Biol. | pmid:23341182 |
| De Angelis C et al. | Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine. | 2013 May-Jun | Tumori | pmid:24158083 |
| Poon KA et al. | Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability. | 2013 | Toxicol. Appl. Pharmacol. | pmid:24035823 |
| Wehrli W | Ansamycins. Chemistry, biosynthesis and biological activity. | 1977 | Top Curr Chem | pmid:74108 |
| Hull RN et al. | Studies on tissue culture produced plasminogen activator. I. Preliminary observations and the enhancing effect of colchicine and other antimitotic agents. | 1977 | Thromb. Res. | pmid:18812 |
| Liang Y et al. | A Nanosystem of Amphiphilic Oligopeptide-Drug Conjugate Actualizing Both αvβ3 Targeting and Reduction-Triggered Release for Maytansinoid. | 2017 | Theranostics | pmid:28900511 |
| Vankemmelbeke M and Durrant L | Third-generation antibody drug conjugates for cancer therapy--a balancing act. | 2016 | Ther Deliv | pmid:26893243 |
| Sieber SM et al. | Teratogenic and cytogenetic effects of some plant-derived antitumor agents (vincristine, colchicine, maytansine, VP-16-213 and VM-26) in mice. | 1978 | Teratology | pmid:694777 |
| Kosmin M et al. | Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer. | 2017 | Target Oncol | pmid:28110417 |
| Diéras V and Bachelot T | The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer. | 2014 | Target Oncol | pmid:23852665 |
| Iwasaki S | [Inhibitors of tubulin assembly: specially on rhizoxin-maytansine site ligands]. | 1993 | Tanpakushitsu Kakusan Koso | pmid:8210422 |
| Janjigian YY and Braghiroli MI | Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Esophagogastric Cancer. | 2017 | Surg. Oncol. Clin. N. Am. | pmid:28279471 |
| Cox K et al. | Emerging Therapeutic Strategies in Breast Cancer. | 2017 | South. Med. J. | pmid:28973703 |
| Bhardwaj AS et al. | A case of vasculitis in a breast cancer patient treated with T-DM1. | 2014 | Semin. Oncol. | pmid:25440614 |
| Müller P et al. | Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. | 2015 | Sci Transl Med | pmid:26606967 |
| Shen K et al. | Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis. | 2016 | Sci Rep | pmid:26979925 |
| Pan W et al. | Asm8, a specific LAL-type activator of 3-amino-5-hydroxybenzoate biosynthesis in ansamitocin production. | 2013 | Sci China Life Sci | pmid:23832249 |
| Ito Y | [Progress of molecularly targeted therapy for breast cancer]. | 2012 | Rinsho Ketsueki | pmid:22687976 |
| Lin CM et al. | Binding of maytansine to tubulin: competition with other mitotic inhibitors. | 1981 | Res. Commun. Chem. Pathol. Pharmacol. | pmid:7255878 |
| Lanshoeft C et al. | Analysis of small molecule antibody-drug conjugate catabolites in rat liver and tumor tissue by liquid extraction surface analysis micro-capillary liquid chromatography/tandem mass spectrometry. | 2016 | Rapid Commun. Mass Spectrom. | pmid:26969923 |
| Lazar AC et al. | Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry. | 2005 | Rapid Commun. Mass Spectrom. | pmid:15945030 |
| Gurtner K et al. | Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo. | 2012 | Radiother Oncol | pmid:22100655 |
| Marcoux J et al. | Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate. | 2015 | Protein Sci. | pmid:25694334 |
| Wang L et al. | Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. | 2005 | Protein Sci. | pmid:16081651 |
| Kubizek F et al. | Status Quo in Antibody-Drug Conjugates - Can Glyco- Enzymes Solve the Current Challenges? | 2017 | Protein Pept. Lett. | pmid:28741467 |
| Sinha S and Jain S | Natural products as anticancer agents. | 1994 | Prog Drug Res | pmid:7916160 |
| Arvanitis CD et al. | Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption. | 2018 | Proc. Natl. Acad. Sci. U.S.A. | pmid:30150398 |
| Field JJ et al. | A previously undescribed tubulin binder. | 2014 | Proc. Natl. Acad. Sci. U.S.A. | pmid:25187564 |
| Prota AE et al. | A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs. | 2014 | Proc. Natl. Acad. Sci. U.S.A. | pmid:25114240 |
| Liu C et al. | Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. | 1996 | Proc. Natl. Acad. Sci. U.S.A. | pmid:8710920 |
| Baskin F et al. | Correlation of double-minute chromosomes with unstable multidrug cross-resistance in uptake mutants of neuroblastoma cells. | 1981 | Proc. Natl. Acad. Sci. U.S.A. | pmid:6943568 |
| Rai SS and Wolff J | The C terminus of beta-tubulin regulates vinblastine-induced tubulin polymerization. | 1998 | Proc. Natl. Acad. Sci. U.S.A. | pmid:9539723 |
| Yu TW et al. | The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretiosum. | 2002 | Proc. Natl. Acad. Sci. U.S.A. | pmid:12060743 |
| Ismaili N et al. | [Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer]. | 2013 | Presse Med | pmid:23721860 |
| Venghateri JB et al. | Ansamitocin P3 depolymerizes microtubules and induces apoptosis by binding to tubulin at the vinblastine site. | 2013 | PLoS ONE | pmid:24124473 |
| Chung YC et al. | Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1). | 2015 | PLoS ONE | pmid:26172389 |
| Beerli RR et al. | Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency. | 2015 | PLoS ONE | pmid:26132162 |
| Goldmacher VS et al. | High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction. | 2015 | PLoS ONE | pmid:25671541 |
| Pullen CB et al. | Occurrence and non-detectability of maytansinoids in individual plants of the genera Maytenus and Putterlickia. | 2003 | Phytochemistry | pmid:12620351 |
| Wings S et al. | A study of the bacterial community in the root system of the maytansine containing plant Putterlickia verrucosa. | 2013 | Phytochemistry | pmid:22795602 |
| Hinow P et al. | Modeling the effects of drug binding on the dynamic instability of microtubules. | 2011 | Phys Biol | pmid:21836336 |
| Jerjian TV et al. | Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy. | 2016 | Pharmacotherapy | pmid:26799352 |
| Hamel E | Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. | 1992 | Pharmacol. Ther. | pmid:1287674 |
| Squires H et al. | Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. | 2016 | Pharmacoeconomics | pmid:26892972 |
| Lai KC et al. | Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay. | 2015 | Pharm. Res. | pmid:25630819 |
| Wood AC et al. | Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. | 2013 | Pediatr Blood Cancer | pmid:23798344 |
| Wang L et al. | Formal total synthesis of N-methylmaysenine. | 2009 | Org. Lett. | pmid:19296671 |
| Meyer A et al. | Chemoenzymatic approaches toward dechloroansamitocin P-3. | 2007 | Org. Lett. | pmid:17378571 |
| Frenzel T et al. | Synthesis of the N-acetylcysteamine thioester of seco-proansamitocin. | 2006 | Org. Lett. | pmid:16381586 |
| Mancuso L et al. | Bioreduction of aryl azides during mutasynthesis of new ansamitocins. | 2013 | Org. Lett. | pmid:23981134 |
| van Boxtel W et al. | Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma. | 2017 | Oral Oncol. | pmid:28673692 |
| Riechelmann H et al. | Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. | 2008 | Oral Oncol. | pmid:18203652 |
| Montero JC et al. | Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling. | 2015 | Oncotarget | pmid:26336133 |
| Nonagase Y et al. | Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1. | 2016 | Oncotarget | pmid:27768588 |
| Raja SM et al. | Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition. | 2016 | Oncotarget | pmid:26859680 |
| Pegram M | Treatment combinations for HER2-positive breast cancer. | 2013 | Oncology (Williston Park, N.Y.) | pmid:23781688 |
| Ranson M and Sliwkowski MX | Perspectives on anti-HER monoclonal antibodies. | 2002 | Oncology | pmid:12422051 |
| Mujagić H and Mujagić Z | Detection of pleiotropic drug resistance by the rapid immunofluorescence assay of drug effects on the cell skeleton. | 1991 | Oncology | pmid:2023698 |
| Lynce F et al. | SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. | 2017 | Oncologist | pmid:28314836 |
| Kan S et al. | Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine. | 2015 | Oncol. Rep. | pmid:25976081 |
| Yamashita-Kashima Y et al. | Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model. | 2013 | Oncol. Rep. | pmid:23783223 |
| Hussar DA | New drugs 2014, part 3. | 2014 | Nursing | pmid:25153167 |
| Johnson MS | The top 10 drug trends right now. | 2013 | Nurs Manage | pmid:23764906 |
| Carlson JA et al. | Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. | 2014 | Neuro-oncology | pmid:24497407 |
| Ponte JF et al. | Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. | 2016 | Neoplasia | pmid:27889646 |
| Wright J | Nanotechnology: Deliver on a promise. | 2014 | Nature | pmid:24870822 |
| Higashide E et al. | Ansamitocin, a group of novel maytansinoid antibiotics with antitumour properties from Nocardia. | 1977 Dec 22-29 | Nature | pmid:593392 |
| Eisenstein M | Medicine: Eyes on the target. | 2015 | Nature | pmid:26580159 |
| Wei GZ et al. | A new antitumour ansamitocin from Actinosynnema pretiosum. | 2010 | Nat. Prod. Res. | pmid:20582809 |
| Siyu-Mao et al. | Two novel ansamitocin analogs from Actinosynnema pretiosum. | 2013 | Nat. Prod. Res. | pmid:23061718 |
| Allison M | Can cancer clinical trials be fixed? | 2011 | Nat. Biotechnol. | pmid:21221090 |
| Shen BQ et al. | Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. | 2012 | Nat. Biotechnol. | pmid:22267010 |
| DeFrancesco L | Drug pipeline: 1Q13. | 2013 | Nat. Biotechnol. | pmid:23752422 |
| Beck A et al. | Strategies and challenges for the next generation of antibody-drug conjugates. | 2017 | Nat Rev Drug Discov | pmid:28303026 |
| Zolot RS et al. | Antibody-drug conjugates. | 2013 | Nat Rev Drug Discov | pmid:23535930 |
| Villanueva MT | Targeted therapies: TH3RESA trial, overcoming hurdles in breast cancer. | 2014 | Nat Rev Clin Oncol | pmid:24913372 |
| Kang Q et al. | Biosynthesis of 3,5-AHBA-derived natural products. | 2012 | Nat Prod Rep | pmid:22193711 |
| Menchon G et al. | A fluorescence anisotropy assay to discover and characterize ligands targeting the maytansine site of tubulin. | 2018 | Nat Commun | pmid:29844393 |
| Adams SR et al. | Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. | 2016 | Nat Commun | pmid:27698471 |
| Zhong P et al. | cRGD-installed docetaxel-loaded mertansine prodrug micelles: redox-triggered ratiometric dual drug release and targeted synergistic treatment of B16F10 melanoma. | 2017 | Nanotechnology | pmid:28574851 |
| He X et al. | Inflammatory Monocytes Loading Protease-Sensitive Nanoparticles Enable Lung Metastasis Targeting and Intelligent Drug Release for Anti-Metastasis Therapy. | 2017 | Nano Lett. | pmid:28758755 |
| Teicher BA and Doroshow JH | The promise of antibody-drug conjugates. | 2012 | N. Engl. J. Med. | pmid:23134386 |
| Verma S et al. | Trastuzumab emtansine for HER2-positive advanced breast cancer. | 2012 | N. Engl. J. Med. | pmid:23020162 |
| Hamblett KJ et al. | Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability. | 2016 | Mol. Pharm. | pmid:27248573 |
| Hong EE et al. | Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation. | 2015 | Mol. Pharm. | pmid:25856201 |
| Widdison W et al. | Metabolites of antibody-maytansinoid conjugates: characteristics and in vitro potencies. | 2015 | Mol. Pharm. | pmid:25826705 |
| Salomon PL and Singh R | Sensitive ELISA Method for the Measurement of Catabolites of Antibody-Drug Conjugates (ADCs) in Target Cancer Cells. | 2015 | Mol. Pharm. | pmid:25738394 |
| Fishkin N | Maytansinoid-BODIPY Conjugates: Application to Microscale Determination of Drug Extinction Coefficients and for Quantification of Maytansinoid Analytes. | 2015 | Mol. Pharm. | pmid:25738231 |
| Goldmacher VS et al. | Statistics of the distribution of the abundance of molecules with various drug loads in maytansinoid antibody-drug conjugates. | 2015 | Mol. Pharm. | pmid:25635630 |
| Barginear MF et al. | Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. | 2012 | Mol. Med. | pmid:23196784 |
| Oroudjev E et al. | Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. | 2010 | Mol. Cancer Ther. | pmid:20937595 |